{"title":"对第一阶段临床试验的无形世界的惊人观察:吉尔·费舍尔不良事件的书评","authors":"R. Richards","doi":"10.1080/14636778.2020.1868989","DOIUrl":null,"url":null,"abstract":"It is her analysis of how the latter process is instrumental in not only providing the Phase 1 industry with ready access to a pool of dedicated volunteers but also serves to generate data that presents pharmaceutical products in the best and safest way, that demonstrates how social inequalities are exploited for systematic profiteering by the pharmaceutical sector. This quote succinctly encapsulates the argument laid out in Jill A. Fisher's \"Adverse Events\": the Phase 1 clinical trial industry in the US not only relies upon but also exploits the social inequalities of the society in which it operates. [Extracted from the article] Copyright of New Genetics & Society is the property of Routledge and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)","PeriodicalId":54724,"journal":{"name":"New Genetics and Society","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2021-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Striking Look into the Invisible World of Phase 1 Clinical Trials: A Book Review of Jill Fisher's Adverse Events\",\"authors\":\"R. Richards\",\"doi\":\"10.1080/14636778.2020.1868989\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"It is her analysis of how the latter process is instrumental in not only providing the Phase 1 industry with ready access to a pool of dedicated volunteers but also serves to generate data that presents pharmaceutical products in the best and safest way, that demonstrates how social inequalities are exploited for systematic profiteering by the pharmaceutical sector. This quote succinctly encapsulates the argument laid out in Jill A. Fisher's \\\"Adverse Events\\\": the Phase 1 clinical trial industry in the US not only relies upon but also exploits the social inequalities of the society in which it operates. [Extracted from the article] Copyright of New Genetics & Society is the property of Routledge and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)\",\"PeriodicalId\":54724,\"journal\":{\"name\":\"New Genetics and Society\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2021-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New Genetics and Society\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14636778.2020.1868989\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Genetics and Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14636778.2020.1868989","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
她分析了后一个过程如何发挥作用,不仅为第一阶段的制药行业提供了现成的志愿者资源,还有助于生成以最佳和最安全的方式呈现制药产品的数据,这表明了制药行业是如何利用社会不平等进行系统性暴利的。这句话简洁地概括了Jill A. Fisher在《不良事件》中提出的观点:美国的第一阶段临床试验行业不仅依赖而且利用了它所处社会的社会不平等。【摘自文章】《新遗传与社会》的版权是Routledge的财产,未经版权所有者的明确书面许可,其内容不得复制或通过电子邮件发送到多个网站或发布到listserv。但是,用户可以打印、下载或通过电子邮件发送文章供个人使用。这篇摘要可以删节。对副本的准确性不作任何保证。用户应参考资料的原始出版版本以获取完整摘要。(版权适用于所有摘要。)
A Striking Look into the Invisible World of Phase 1 Clinical Trials: A Book Review of Jill Fisher's Adverse Events
It is her analysis of how the latter process is instrumental in not only providing the Phase 1 industry with ready access to a pool of dedicated volunteers but also serves to generate data that presents pharmaceutical products in the best and safest way, that demonstrates how social inequalities are exploited for systematic profiteering by the pharmaceutical sector. This quote succinctly encapsulates the argument laid out in Jill A. Fisher's "Adverse Events": the Phase 1 clinical trial industry in the US not only relies upon but also exploits the social inequalities of the society in which it operates. [Extracted from the article] Copyright of New Genetics & Society is the property of Routledge and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
期刊介绍:
New Genetics and Society: Critical Studies of Contemporary Biosciences is a world-leading journal which:
-Provides a focus for interdisciplinary and multi-disciplinary, leading-edge social science research on the new genetics and related biosciences;
-Publishes theoretical and empirical contributions reflecting its multi-faceted development;
-Provides an international platform for critical reflection and debate;
-Is an invaluable research resource for the many related professions, including health, medicine and the law, wishing to keep abreast of fast changing developments in contemporary biosciences.
New Genetics and Society publishes papers on the social aspects of the new genetics (widely defined), including gene editing, genomics, proteomics, epigenetics and systems biology; and the rapidly developing biosciences such as biomedical and reproductive therapies and technologies, xenotransplantation, stem cell research and neuroscience. Our focus is on developing a better understanding of the social, legal, ethical and policy aspects, including their local and global management and organisation.